Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Gend Med ; 9(3): 166-179.e13, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22361840

ABSTRACT

BACKGROUND: Nutritional conditions during fetal life influence the risk of the development of metabolic syndrome and cardiovascular diseases in adult life (metabolic programming). Impaired glucose tolerance and dysregulated fatty acid metabolism are hallmarks of metabolic syndrome. OBJECTIVE: We aimed to establish a mouse model of metabolic programming focusing on the sex-specific effects of a maternal low-protein diet during gestation on glucose and lipid metabolism in the adult offspring. METHODS: Pregnant C57BL/6 mice received a control or a low-protein diet (18% vs 9% casein) throughout gestation. Male and female offspring received a low-fat or a high-fat diet from 6 to 22 weeks of age. RESULTS: Maternal low-protein diet during gestation led to deteriorated insulin sensitivity on high-fat feeding in female offspring, as determined by biochemical and microarray analyses. Female offspring of control diet-fed dams were relatively resistant to high-fat diet-induced metabolic dysregulation. In contrast, maternal low-protein diet did not specifically affect the metabolic parameters addressed in male offspring. In males, the high-fat diet led to insulin insensitivity regardless of the diet of the dam. CONCLUSIONS: Our findings show that fetal malnutrition has a limited impact on male mouse offspring, yet it does influence the metabolic response to a high-fat diet in females. These findings may have implications for future early diagnostics in metabolic syndrome and for the development of sex-specific treatment regimens.


Subject(s)
Diet, Protein-Restricted/adverse effects , Fatty Acids/metabolism , Glucose/metabolism , Metabolic Syndrome/etiology , Prenatal Exposure Delayed Effects , Prenatal Nutritional Physiological Phenomena , Adult , Animals , Diet, High-Fat , Female , Humans , Male , Mice , Pregnancy , Sex Factors
2.
Eur J Cancer ; 47(10): 1595-602, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21429739

ABSTRACT

PURPOSE: A feasibility study was performed to investigate the presence of VEGF in melanoma lesions by VEGF-SPECT with (111)In-bevacizumab. In addition the effect of a single therapeutic bevacizumab dose on (111)In-bevacizumab uptake was compared with VEGF levels in resected melanoma lesions. PATIENTS AND METHODS: Eligible were patients with stage III/IV melanoma who presented with nodal recurrent disease. VEGF-SPECT was performed after administration of 100 Mbq (111)In-bevacizumab (8 mg) at days 0, 2, 4 and 7 post injection. Tumour visualisation and quantification were compared with CT and FDG-PET. On day 7 a single dose of 7.5mg/kg bevacizumab was administered intravenously. On day 21, a second tracer dose (111)In-bevacizumab was administered and scans were obtained on days 21, 25 and 28. Metastases were surgically resected within 2 weeks after the last VEGF-SPECT scan and immunohistological (IHC) VEGF tumour expression was compared with (111)In-bevacizumab tumour uptake. RESULTS: Nine patients were included. FDG-PET and CT detected both in total 12 nodal lesions which were all visualised by VEGF-SPECT. At baseline, (111)In-bevacizumab tumour uptake varied 3-fold between and 1.6 ± 0.1-fold within patients. After a therapeutic dose of bevacizumab there was a 21 ± 4% reduction in (111)In-bevacizumab uptake. The (111)In-bevacizumab tumour uptake in the second series positively correlated with the VEGF-A expression in the resected tumour lesions. CONCLUSION: VEGF-SPECT could visualise all known melanoma lesions. A single dose of bevacizumab slightly lowered (111)In-bevacizumab uptake. Future studies should elucidate the role of VEGF-SPECT in the selection of patients and the individual dosing of bevacizumab treatment.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Melanoma/drug therapy , Melanoma/pathology , Tomography, Emission-Computed, Single-Photon/methods , Vascular Endothelial Growth Factor A/metabolism , Adult , Bevacizumab , Female , Humans , Image Processing, Computer-Assisted , Immunohistochemistry/methods , Indium Radioisotopes/chemistry , Infusions, Intravenous/methods , Male , Middle Aged , Neoplasm Metastasis , Time Factors
3.
Pediatr Res ; 68(1): 10-5, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20386142

ABSTRACT

Intrauterine malnutrition is associated with increased susceptibility to chronic diseases in adulthood. Growth-restricted infants display a less favorable lipid profile already shortly postnatal. Maternal low protein diet (LPD) during gestation is a well-defined model of fetal programming in rodents and affects lipid metabolism of the offspring. Effects of LPD throughout gestation on physiologic relevant parameters of lipid metabolism are unclear. We aimed to determine effects of LPD on maternal-fetal cholesterol fluxes and fetal lipid synthesis in mice. Pregnant mice (dams) were fed with a control (18% casein) or an LPD (9% casein) from E0.5 onward. We quantified maternal-fetal cholesterol transport and maternal cholesterol absorption at E19.5 using stable isotopes. We determined fetal lipid biosynthesis at E19.5, after administration of (1-C)-acetate from E17.5 onward. LPD did not change fetal and maternal plasma and hepatic concentrations of cholesterol and triglycerides. LPD affected neither the magnitudes of maternal-fetal cholesterol flux, maternal cholesterol absorption, nor fetal synthesis of cholesterol and palmitate (both groups, approximately 14% and approximately 13%, respectively). We conclude that LPD throughout gestation in mice does not affect maternal-fetal cholesterol transport, fetal cholesterol or fatty acid synthesis, indicating that programming effects of LPD are not mediated by short-term changes in maternal-fetal lipid metabolism.


Subject(s)
Cholesterol/metabolism , Fetal Nutrition Disorders/metabolism , Lipids/biosynthesis , Maternal-Fetal Exchange/physiology , Placental Insufficiency/metabolism , Adult , Animals , Body Weight , Female , Fetal Growth Retardation/metabolism , Fetus/anatomy & histology , Fetus/metabolism , Gestational Age , Humans , Male , Mice , Mice, Inbred C57BL , Pregnancy , Prenatal Exposure Delayed Effects/metabolism
4.
Am J Physiol Regul Integr Comp Physiol ; 298(2): R275-82, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19889862

ABSTRACT

Prenatal nutrition as influenced by the nutritional status of the mother has been identified as a determinant of adult disease. Feeding low-protein diets during pregnancy in rodents is a well-established model to induce programming events in offspring. We hypothesized that protein restriction would influence fetal lipid metabolism by inducing epigenetic adaptations. Pregnant C57BL/6J mice were exposed to a protein-restriction protocol (9% vs. 18% casein). Shortly before birth, dams and fetuses were killed. To identify putative epigenetic changes, CG-dinucleotide-rich region in the promoter of a gene (CpG island) methylation microarrays were performed on DNA isolated from fetal livers. Two hundred four gene promoter regions were differentially methylated upon protein restriction. The liver X-receptor (Lxr) alpha promoter was hypermethylated in protein-restricted pups. Lxr alpha is a nuclear receptor critically involved in control of cholesterol and fatty acid metabolism. The mRNA level of Lxra was reduced by 32% in fetal liver upon maternal protein restriction, whereas expression of the Lxr target genes Abcg5/Abcg8 was reduced by 56% and 51%, respectively, measured by real-time quantitative PCR. The same effect, although less pronounced, was observed in the fetal intestine. In vitro methylation of a mouse Lxra-promoter/luciferase expression cassette resulted in a 24-fold transcriptional repression. Our study demonstrates that, in mice, protein restriction during pregnancy interferes with DNA methylation in fetal liver. Lxra is a target of differential methylation, and Lxra transcription is dependent on DNA methylation. It is tempting to speculate that perinatal nutrition may influence adult lipid metabolism by DNA methylation, which may contribute to the epidemiological relation between perinatal/neonatal nutrition and adult disease.


Subject(s)
DNA Methylation/drug effects , Orphan Nuclear Receptors/genetics , Prenatal Exposure Delayed Effects/genetics , Prenatal Exposure Delayed Effects/metabolism , Promoter Regions, Genetic/genetics , Protein-Energy Malnutrition/genetics , Protein-Energy Malnutrition/metabolism , Animals , Base Sequence , Birth Weight/physiology , Body Weight/physiology , COS Cells , Chlorocebus aethiops , CpG Islands/genetics , Cytidine/analogs & derivatives , Cytidine/pharmacology , Diet , Epigenesis, Genetic , Female , Lipid Metabolism/genetics , Lipid Metabolism/physiology , Liver/drug effects , Liver/metabolism , Liver X Receptors , Male , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Oligonucleotide Array Sequence Analysis , Pregnancy
5.
Am J Physiol Endocrinol Metab ; 297(5): E1171-8, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19724022

ABSTRACT

There is increasing evidence that the metabolic state of the mother during pregnancy affects long-term glucose and lipid metabolism of the offspring. The liver X receptors (LXR)α and -ß are key regulators of cholesterol, fatty acid, and glucose metabolism. LXRs are activated by oxysterols and expressed in fetal mouse liver from day 10 of gestation onward. In the present study, we aimed to elucidate whether in utero pharmacological activation of LXR would influence fetal fatty acid and glucose metabolism and whether this would affect lipid homeostasis at adult age. Exposure of pregnant mice to the synthetic LXR agonist T0901317 increased hepatic mRNA expression levels of Lxr target genes and hepatic and plasma triglyceride levels in fetuses and dams. T0901317 treatment increased absolute de novo synthesis and chain elongation of hepatic oleic acid in dams and fetuses. T0901317 exposure in utero influenced lipid metabolism in adulthood in a sex-specific manner; hepatic triglyceride content was increased (+45%) in male offspring and decreased in female offspring (-42%) when they were fed a regular chow diet compared with untreated sex controls. Plasma and hepatic lipid contents and hepatic gene expression patterns in adult male or female mice fed a high-fat diet were not affected by T0901317 pretreatment. We conclude that LXR treatment of pregnant mice induces immediate effects on lipid metabolism in dams and fetuses. Despite the profound changes during fetal life, long-term effects appeared to be rather mild and sex selective without modulating the lipid response to a high-fat diet.


Subject(s)
Diet, High-Fat/adverse effects , Dietary Fats/pharmacology , Hydrocarbons, Fluorinated/pharmacology , Lipids/blood , Lipogenesis/drug effects , Orphan Nuclear Receptors/metabolism , Sulfonamides/pharmacology , Animals , Fatty Acids, Nonesterified/metabolism , Fatty Liver/chemically induced , Fatty Liver/metabolism , Female , Fetal Development/physiology , Fetus/metabolism , Glucose/metabolism , Homeostasis/drug effects , Insulin/physiology , Liver X Receptors , Male , Mice , Mice, Inbred C57BL , Oleic Acids/biosynthesis , Orphan Nuclear Receptors/agonists , Pregnancy , RNA/biosynthesis , RNA/isolation & purification , Real-Time Polymerase Chain Reaction , Sex Characteristics
6.
J Biol Chem ; 281(2): 934-44, 2006 Jan 13.
Article in English | MEDLINE | ID: mdl-16272564

ABSTRACT

Proteins secreted from adipose tissue are increasingly recognized to play an important role in the regulation of glucose metabolism. However, much less is known about their effect on lipid metabolism. The fasting-induced adipose factor (FIAF/angiopoietin-like protein 4/peroxisome proliferator-activated receptor gamma angiopoietin-related protein) was previously identified as a target of hypolipidemic fibrate drugs and insulin-sensitizing thiazolidinediones. Using transgenic mice that mildly overexpress FIAF in peripheral tissues we show that FIAF is an extremely powerful regulator of lipid metabolism and adiposity. FIAF overexpression caused a 50% reduction in adipose tissue weight, partly by stimulating fatty acid oxidation and uncoupling in fat. In addition, FIAF overexpression increased plasma levels of triglycerides, free fatty acids, glycerol, total cholesterol, and high density lipoprotein (HDL)-cholesterol. Functional tests indicated that FIAF overexpression severely impaired plasma triglyceride clearance but had no effect on very low density lipoprotein production. The effects of FIAF overexpression were amplified by a high fat diet, resulting in markedly elevated plasma and liver triglycerides, plasma free fatty acids, and plasma glycerol levels, and impaired glucose tolerance in FIAF transgenic mice fed a high fat diet. Remarkably, in mice the full-length form of FIAF was physically associated with HDL, whereas truncated FIAF was associated with low density lipoprotein. In human both full-length and truncated FIAF were associated with HDL. The composite data suggest that via physical association with plasma lipoproteins, FIAF acts as a powerful signal from fat and other tissues to prevent fat storage and stimulate fat mobilization. Our data indicate that disturbances in FIAF signaling might be involved in dyslipidemia.


Subject(s)
Adipose Tissue/metabolism , Blood Proteins/genetics , Blood Proteins/physiology , Lipoproteins/chemistry , Angiopoietin-Like Protein 4 , Angiopoietins , Animals , Blood Proteins/chemistry , Body Weight , Cholesterol/metabolism , Fats/chemistry , Gene Expression , Glucose/metabolism , Glucose Tolerance Test , Humans , Hypercholesterolemia/metabolism , Immunoblotting , Insulin/metabolism , Lipase/metabolism , Lipids/chemistry , Lipoproteins, HDL/chemistry , Lipoproteins, HDL/metabolism , Lipoproteins, LDL/chemistry , Lipoproteins, VLDL/chemistry , Liver/enzymology , Male , Mice , Mice, Transgenic , Models, Genetic , Oligonucleotide Array Sequence Analysis , Protein Binding , RNA, Messenger/metabolism , Signal Transduction , Time Factors , Triglycerides/blood , Triglycerides/metabolism , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...